Chen Bihua 4
4 · BridgeBio Oncology Therapeutics, Inc. · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
BBOT 10% Owner Bihua Chen Reallocates Shares (No Cash)
What Happened
Bihua Chen, a director and reported 10% owner related to Helix Holdings II LLC (the "Sponsor"), reported a series of related-party reallocation transactions on 2026-07-01. The Form 4 shows: 4,528,186 shares disposed (reported at $0) and three acquisitions totaling 4,528,186 shares (2,692,459; 1,704,862; and 130,865) also reported at $0. All transactions are coded as "J" (other acquisition or disposition) and carry no cash value — this was an internal, pro rata distribution among Sponsor members, not an open-market buy or sell.
Key Details
- Transaction date: 2026-07-01; Filing date: 2026-07-06 (as filed with the SEC).
- Reported amounts and prices: Disposed 4,528,186 shares @ $0.00; Acquired 2,692,459 @ $0.00, 1,704,862 @ $0.00, 130,865 @ $0.00. Net cash = $0.
- Shares owned after transaction: The filing shows the Sponsor as the record holder and does not report a separate beneficial ownership total for Ms. Chen beyond the disclaimers in the footnotes.
- Footnotes summary: Transactions were pro rata distributions by the Sponsor for no consideration (F1). Cormorant-managed funds (Fund III, Fund V, Master Fund) received pro rata distributions and are Sponsor members (F2–F4). Ms. Chen is manager of the Sponsor and the general partner/manager of related entities and has voting/investment discretion but disclaims beneficial ownership except to the extent of any pecuniary interest (F5–F6). The filing notes Ms. Chen serves on the issuer’s board and that Sponsor/Cormorant Funds may be deemed directors by deputization.
Context
- These entries reflect an internal reallocation among affiliated entities (a pro rata distribution) rather than a market sale or purchase; they do not indicate funds changing hands or open-market sentiment.
- For retail investors, such related-party transfers typically reflect ownership structuring among funds and the Sponsor; they are not direct buy/sell signals by the insider for personal investment decisions.
Insider Transaction Report
Form 4
Chen Bihua
Director10% Owner
Transactions
- Other
Common Stock
[F1][F5]2026-07-01−4,528,186→ 0 total(indirect: By LLC) - Other
Common Stock
[F2][F6]2026-07-01+2,692,459→ 4,879,995 total(indirect: Via Fund III) - Other
Common Stock
[F3][F6]2026-07-01+1,704,862→ 5,010,332 total(indirect: Via Fund V) - Other
Common Stock
[F4][F6]2026-07-01+130,865→ 6,083,221 total(indirect: Via Master Fund)
Holdings
- 1,905,046(indirect: Via Fund IV)
Common Stock
[F6]
Footnotes (6)
- [F1]Represents a pro rata distribution to the members of Helix Holdings II LLC (the "Sponsor") for no consideration.
- [F2]Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP ("CAM"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- [F3]Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- [F4]Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
- [F5]Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly.
- [F6]CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Signature
/s/ Bihua Chen|2026-07-06